[{"id":"3cd29e52-af9d-4ffc-9f57-b8ce426e67cb","acronym":"","url":"https://clinicaltrials.gov/study/NCT05661201","created_at":"2022-12-22T15:59:18.931Z","updated_at":"2024-07-02T16:35:15.432Z","phase":"Phase 1","brief_title":"NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors","source_id_and_acronym":"NCT05661201","lead_sponsor":"Georgetown University","biomarkers":" KRAS • ST2","pipe":" | ","alterations":" KRAS mutation","tags":["KRAS • ST2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • Nerofe (84AA-API 14AA)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 04/12/2023","start_date":" 04/12/2023","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2024-03-11"},{"id":"7d8b0eef-b03c-4911-b4a7-b91df81c3ecd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04365179","created_at":"2022-01-21T23:05:16.500Z","updated_at":"2024-07-02T16:36:06.876Z","phase":"Phase 1b","brief_title":"Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced MDS and AML","source_id_and_acronym":"NCT04365179","lead_sponsor":"Immune System Key Ltd","biomarkers":" ST2","pipe":"","alterations":" ","tags":["ST2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nerofe (84AA-API 14AA)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 06/18/2020","start_date":" 06/18/2020","primary_txt":" Primary completion: 12/30/2022","primary_completion_date":" 12/30/2022","study_txt":" Completion: 12/30/2022","study_completion_date":" 12/30/2022","last_update_posted":"2022-07-22"},{"id":"58a31459-21df-4bd9-8abf-d104cc8e0d3c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03634150","created_at":"2022-01-21T23:04:46.298Z","updated_at":"2024-07-02T16:36:22.458Z","phase":"Phase 1b","brief_title":"Safety and Efficacy of IV Nerofe™ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer","source_id_and_acronym":"NCT03634150","lead_sponsor":"Immune System Key Ltd","biomarkers":" ST2","pipe":"","alterations":" ","tags":["ST2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • Nerofe (84AA-API 14AA)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/06/2018","start_date":" 09/06/2018","primary_txt":" Primary completion: 04/21/2020","primary_completion_date":" 04/21/2020","study_txt":" Completion: 04/21/2020","study_completion_date":" 04/21/2020","last_update_posted":"2021-10-26"},{"id":"0ab959d2-019e-4284-83c4-b2da168d5e81","acronym":"","url":"https://clinicaltrials.gov/study/NCT03059615","created_at":"2022-01-21T23:03:21.504Z","updated_at":"2024-07-02T16:36:42.508Z","phase":"Phase 2a","brief_title":"A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDS","source_id_and_acronym":"NCT03059615","lead_sponsor":"Immune System Key Ltd","biomarkers":" ST2","pipe":"","alterations":" ","tags":["ST2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • Nerofe (84AA-API 14AA)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/25/2018","start_date":" 10/25/2018","primary_txt":" Primary completion: 07/26/2020","primary_completion_date":" 07/26/2020","study_txt":" Completion: 07/26/2020","study_completion_date":" 07/26/2020","last_update_posted":"2020-07-31"},{"id":"35c486d5-bfcb-4625-9d4c-ee6c0baceebb","acronym":"","url":"https://clinicaltrials.gov/study/NCT01690741","created_at":"2022-01-21T22:57:20.249Z","updated_at":"2024-07-02T16:37:09.631Z","phase":"Phase 1","brief_title":"Phase 1 Trial of Intravenously Administered Nerofe™ in Subjects With Advanced Malignancies","source_id_and_acronym":"NCT01690741","lead_sponsor":"Immune System Key Ltd","biomarkers":" ST2","pipe":"","alterations":" ","tags":["ST2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nerofe (84AA-API 14AA)"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 12/01/2013","start_date":" 12/01/2013","primary_txt":" Primary completion: 12/19/2017","primary_completion_date":" 12/19/2017","study_txt":" Completion: 12/19/2017","study_completion_date":" 12/19/2017","last_update_posted":"2018-06-25"}]